Can mycophenolate mofetil substitute cyclophosphamide treatment of pediatric lupus nephritis?

Pediatric Nephrology

Volumn 22, Issue 8, 2007, Pages 1077-1082

  Paredes, Ana ^a  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

Children; Cyclophosphamide; Induction; Lupus; Mycophenolate mofetil; Nephritis

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CHILDHOOD DISEASE; DRUG SUBSTITUTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; CHILD; COMPARATIVE STUDY; EDITORIAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID;

EID: 34548402653     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-007-0463-9     Document Type: Article

References (20)

1. Boumpas DT, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745
2. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945–950
3. Illei GG, Austin HA, Crane M, Colins MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248–257
4. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized controlled trial. Ann Intern Med 125:549–570
5. Mok CC, Lau CS, Wong RW (1998) Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41:831–837
6. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369
7. Mok CC, Ying KY, Tsang S, Leung CY, Lee KW, Mg WL, Wong RW, Lau CS (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559–2568
8. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos HM (2000) Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 57:258–264
9. Allison AC (2005) Mechanisms of action of mycophenolate mofetil. Lupus 14:s2–s8
10. Lenz O, Fornoni A, Contreras G (2005) Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis. Drugs 65:2429–2436
11. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG (2003) Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 62:534–539
12. Briggs WA, Choi MJ, Scheel PJ Jr (1998) Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis 31:213–217
13. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA (1999) Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 10:833–839
14. Chan TM, Li FK, Tsang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343:1156–1162
15. Chan TM, Tse KC, Tang CS, Mok MY, Li FK (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16:1076–1084
16. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 10:504–510
17. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353:2219–2228
18. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus nephritis Trial, a randomized trial of low dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131
19. Pecoraro C, Malgieri G, D’Armiento M, Balletta MM, Nuzzi F, Caropreso M (2005) Treatment of childhood lupus nephritis with mycophenolate mofetil: clinical and histopathological study. J Am Soc Nephrol 16:557A
20. Lau KL, Jones DP, Hastings MC, Gaber LW, Ault BH (2006) Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol 21:655–662